MedTrace Logo

Activity of Bioactive Natural Compounds as Potential Agonists of GLP1R

NCT06513715 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-07-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if natural bioactive compound jubenine works to reduce appetite and to favour weight loss. It will also learn about the safety of natural bioactive compound jubenine. The main questions it aims to answer are:

Does natural bioactive compound jubenine reduce the hunger perception or increase the satiety perception, and, consequently, reduce food intake? What medical problems do participants have when taking natural bioactive compound jubenine? Researchers will compare natural bioactive compound jubenine to a placebo (a look-alike substance that contains no drug) to see if natural bioactive compound jubenine works to reduce food intake for obesity treatment.

Participants will:

Take natural bioactive compound jubenine or a placebo three times every day for 3 months.

Visit the clinic once every 1 week for checkups and tests. Keep a diary of their symptoms and potenital adverse effects.

Conditions

Interventions

DIETARY_SUPPLEMENT

Control

This intervention will be made with a placebo

DIETARY_SUPPLEMENT

Jubanine

This intervention will be made with jubanine or prickly pear extract

Sponsors & Collaborators

  • Universidad Católica San Antonio de Murcia

    lead OTHER

Principal Investigators

  • Juan José Hernández Morante, PhD · Universidad Católica San Antonio de Murcia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-09
Primary Completion
2026-01-31
Completion
2026-07-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06513715 on ClinicalTrials.gov